IP Library Granted Patent US 8,957,050
Granted Patent B2
US 8,957,050 · App. 13/793,644 · Granted Feb 17, 2015

Bone implant materials comprising cross-linked bioactive hydrogel matrices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,957,050
App. No.
13/793,644
Granted
Feb 17, 2015
Kind
B2
Abstract

The present invention is directed to a stabilized cross-linked hydrogel matrix comprising a first high molecular weight component and a second high molecular weight component that are covalently linked, and at least one stabilizing or enhancing agent, wherein the first high molecular weight component and the second high molecular weight component are each selected from the group consisting of polyglycans and polypeptides. This stabilized hydrogel matrix may be prepared as bioactive gels, pastes, slurries, cell attachment scaffolds for implantable medical devices, and casting or binding materials suitable for the construction of medical devices. The intrinsic bioactivity of the hydrogel matrix makes it useful as a gel or paste in multiple applications, including as a cell attachment scaffold that promotes wound healing around an implanted device, as gels and pastes for induction of localized vasculogenesis, wound healing, tissue repair, and regeneration, as a wound adhesive, and for tissue bulking.

Claims (11)

1. A bone implant material formed of a molded composition having a predetermined shape and comprising: a crosslinked bioactive hydrogel matrix comprising a polyglycan crosslinked to a polypeptide, and at least one enhancing agent selected from the group consisting of polar amino acids, intact collagen, divalent cation chelators, and combinations thereof; and an osteoinductive or osteoconductive material comprising hydroxyapatite.

2. The bone implant material of claim 1 , wherein the polyglycan is a polysaccharide or a sulfated polysaccharide.

3. The bone implant material of claim 2 , wherein the polyglycan is selected from the group consisting of glycosaminoglycans, glucosaminoglycans, dextran, heparan, heparin, hyaluronic acid, alginate, agarose, carageenan, amylopectin, amylose, glycogen, starch, cellulose, chitin, heparan sulfate, chondroitin sulfate, dextran sulfate, dermatan sulfate, and keratan sulfate.

4. The bone implant material of claim 1 , wherein the polyglycan has a molecular weight of about 2,000 to about 8,000,000 Da.

5. The bone implant material of claim 1 , wherein the polypeptide is selected from the group consisting of collagens, gelatins, keratin, decorin, aggrecan, glycoproteins, laminin, nidogen, fibulin, and fibrillin.

6. The bone implant material of claim 1 , wherein the polypeptide has a molecular weight of about 3,000 to about 3,000,000 Da.

7. The bone implant material of claim 1 , wherein the polyglycan is dextran and the polypeptide is gelatin.

8. The bone implant material of claim 1 , wherein the at least one enhancing agent comprises at least one polar amino acid selected from the group consisting of tyrosine, cysteine, serine, threonine, asparagine, glutamine, aspartic acid, glutamic acid, arginine, lysine, histidine, and mixtures thereof.

9. The bone implant material of claim 1 , wherein the at least one enhancing agent comprises ethylenediaminetetraacetic acid or a salt thereof.

10. The bone implant material of claim 1 , further comprising at least one additional osteoinductive or osteoconductive material selected from the group consisting of calcium aluminate, hydroxyapatite, alumina, zirconia, aluminum silicates, calcium phosphate, bioactive glass, ceramics, collagen, autologous bone, allogenic bone, xenogenic bone, coralline, and derivates or combinations thereof.

11. The bone implant material of claim 1 , wherein the osteoinductive or osteoconductive material is in the form of a powder.

Assignments (10)
SECURITY INTEREST Recorded Jun 12, 2025
From: PIONEER SURGICAL TECHNOLOGY, INC.; TYBER MEDICAL LLC; SMADE SAS; BRADSHAW MEDICAL INC.; TURNER MEDICAL, INC.; IN’TECH MEDICAL SAS
To: OHA AGENCY LLC, AS COLLATERAL AGENT
Reel/Frame 071575/0563 →
RELEASE OF SECURITY INTEREST Recorded Jul 21, 2020
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.
Reel/Frame 053260/0398 →
RELEASE OF SECURITY INTEREST Recorded Jul 20, 2020
From: ARES CAPITAL CORPORATION, AS AGENT
To: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.; PARADIGM SPINE, LLC; FOURTH DIMENSION SPINE, LLC
Reel/Frame 053257/0652 →
SECURITY INTEREST Recorded Mar 8, 2019
From: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.; PARADIGM SPINE, LLC; FOURTH DIMENSION SPINE, LLC
To: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 048543/0505 →
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2018
From: TD BANK, N.A., AS ADMINISTRATIVE AGENT
To: PIONEER SURGICAL TECHNOLOGY, INC., SUCCESSOR IN INTEREST TO PIONEER SURGICAL ORTHOBIOLOGICS, INC.
Reel/Frame 046016/0132 →
SECURITY INTEREST Recorded Jun 6, 2018
From: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A., AS THE ADMINISTRATIVE AGENT
Reel/Frame 046303/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2013
From: LAMBERTI, FRANCIS V.; KLANN, RICHARD CHRIS; HILL, RONALD STEWART
To: ENCELLE, INC.
Reel/Frame 031721/0941 →
MERGER Recorded Dec 5, 2013
From: ENCELLE, INC.
To: PIONEER SURGICAL ORTHOBIOLOGICS, INC.
Reel/Frame 031722/0013 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2013
From: PIONEER SURGICAL ORTHOBIOLOGICS, INC.
To: PIONEER SURGICAL TECHNOLOGY, INC.
Reel/Frame 031722/0041 →
SECURITY AGREEMENT Recorded Jul 29, 2013
From: PIONEER SURGICAL ORTHOBIOLOGICS, INC.
To: TD BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 030910/0581 →